CELCUITY INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
CELCUITY INC. (CELC) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $16.35 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-13
- CELCUITY INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$20.51M.
- CELCUITY INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$6.04M, a 1193.66% decline year-over-year.
- CELCUITY INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $552.00K, a 93.91% decline year-over-year.
- CELCUITY INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $9.07M.
- CELCUITY INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $143.19M.
- CELCUITY INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$8.15M, a 233.77% decline from fiscal 2023.
- CELCUITY INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $6.09M.
- CELCUITY INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$59.71M, a 182.20% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $16.35M 10-Q · filed 2026-08-13 | |||||||
| 2026-03-31 | -$20.51M 10-Q · filed 2026-05-14 | |||||||
| 2025-12-31 | $143.19M 10-K · filed 2026-03-26 | |||||||
| 2025-09-30 | $51.74M 10-Q · filed 2025-11-13 | |||||||
| 2025-06-30 | $23.84M 10-Q · filed 2026-08-13 | |||||||
| 2025-03-31 | -$6.04M 10-Q · filed 2026-05-14 | |||||||
| 2024-12-31 | -$8.15M 10-K · filed 2026-03-26 | -$8.15M 10-K · filed 2025-03-31 | ||||||
| 2024-09-30 | -$18.06M 10-Q · filed 2025-11-13 | -$18.06M 10-Q · filed 2024-11-14 | ||||||
| 2024-06-30 | -$204.00K 10-Q · filed 2025-08-14 | -$203.97K 10-Q · filed 2024-08-14 | ||||||
| 2024-03-31 | $552.00K 10-Q · filed 2025-05-15 | $551.97K 10-Q · filed 2024-05-15 | ||||||
| 2023-12-31 | $6.09M 10-K · filed 2025-03-31 | |||||||
| 2023-09-30 | $1.19M 10-Q · filed 2024-11-14 | |||||||
| 2023-06-30 | $7.67M 10-Q · filed 2024-08-14 | |||||||
| 2023-03-31 | $9.07M 10-Q · filed 2024-05-15 | |||||||
| 2022-12-31 | -$59.71M 10-K · filed 2024-03-27 | |||||||
| 2022-09-30 | -$26.80M 10-Q · filed 2023-11-13 | |||||||
| 2022-06-30 | -$17.38M 10-Q · filed 2023-08-11 | |||||||
| 2022-03-31 | -$5.99M 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | $72.65M 10-K · filed 2023-03-23 | |||||||
| 2021-09-30 | $78.73M 10-Q · filed 2022-11-10 | |||||||
| 2021-06-30 | $30.00M 10-Q · filed 2022-08-12 | |||||||
| 2021-03-31 | $23.30M 10-Q · filed 2022-05-16 | |||||||
| 2020-12-31 | -$7.10M 10-K · filed 2022-03-23 | |||||||
| 2020-09-30 | -$5.04M 10-Q · filed 2021-11-09 | |||||||
| 2020-03-31 | -$1.88M 10-Q · filed 2020-05-07 | |||||||
| 2019-09-30 | $324.99K 10-Q · filed 2019-11-07 | |||||||
| 2019-06-30 | -$1.03M 10-Q · filed 2019-08-08 | |||||||
| 2019-03-31 | -$1.22M 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | $13.25M 10-K · filed 2019-03-01 | |||||||
| 2018-09-30 | $1.12M 10-Q · filed 2019-11-07 | |||||||
| 2018-06-30 | $532.99K 10-Q · filed 2019-08-08 | |||||||
| 2018-03-31 | -$67.13K 10-Q · filed 2019-05-07 | |||||||
| 2017-12-31 | -$3.22M 10-K · filed 2019-03-01 | |||||||
| 2017-09-30 | $26.45M 10-Q · filed 2018-11-13 | |||||||
| 2017-06-30 | $5.05M 10-Q · filed 2018-08-09 | |||||||
| 2017-03-31 | -$957.52K 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |